HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Like Health And Economic Impact, COVID-19 Unprecedented As Unlawful Claims Driver

Executive Summary

Variety of products advertised with false coronavirus claims also grew in FTC's latest warnings submitted. It warned 21 firms on claims for products including IV drips, ozone therapy and stem cell treatments.

You may also be interested in...



US Hospitals’ COVID-19 Treatment Protocols Aren’t Prescriptions To Make Vitamin C Ad Claims

Marketer of Billy’s Infinity-C supplement line discontinues social media post that COVID-19 patients in hospitals are receiving high doses of vitamin C. BBB National Programs division says the post implies consumers can prevent contracting the virus through vitamin C use. 

US Consumer Health Regulation: Before Warning, Recall For Supplement With COVID-19 Label Claim

Until FDA on 23 June posted report about Golden Nutrition Inc.’s herbal supplement, violative COVID-19 claims had been found online and in advertising through other channels. Other consumer health recalls in US include more than 2.5m bottles of Gaviscon Liquid Antacid missing a safety warning on labels.

US Regulators Shine Warning On Clinic’s Ozone, UV Light, Other Treatments For COVID-19

US FDA and FTC warned a California integrative medicine doctor for offering ozone treatment and UV light therapy to prevent COVID-19 as well as a private blogger and an Amazon vendor who recommended vitamins for preventing the virus.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149948

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel